“Breast Cancer Talk” Review of Data from the SABCS 2020 Virtual Meeting - Episode 1

Metastatic Hormone-Receptor Positive Breast Cancer

January 27, 2021
William J. Gradishar, MD, Northwestern University

Priyanka Sharma, MD, University of Kansas Medical Center

Pavani Chalasani, MD, University of Arizona Cancer Center

The expert panelists highlight data from the virtual San Antonio Breast Cancer Symposium 2020, focusing on hormone receptor-positive breast cancer.

Data from the following abstracts are discussed:

  • “GS1-01. Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Combined with Adjuvant Endocrine Therapy for High Risk Early Breast Cancer” (O’Shaughnessy et al, SABCS 2020)

  • “GS1-02. Phase III Study of Palbociclib Combined With Endocrine Therapy (ET) in Patients With Hormone-Receptor-Positive (HR+), HER2-Negative Primary Breast Cancer and With High Relapse Risk After Neoadjuvant Chemotherapy (NACT): First Results From PENELOPE-B” (Loibl et al, SABCS 2020)

  • “GS4-01. Results from CONTESSA: A Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2-, Hormone Receptor + (HR+) Metastatic Breast Cancer (MBC) Who Have Previously Received a Taxane” (O’Shaughnessy et al, SABCS, 2020)

  • “GS3-00. First Results From a Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy (ET) +/- Chemotherapy (CT) in Patients (pts) with 1-3 Positive Nodes, Hormone Receptor-Positive (HR+) and HER2-negative (HER2-) Breast Cancer (BC) with Recurrence Score (RS) < 25: SWOG S1007 (RxPonder)” (Kalinsky et al, SABCS 2020)

  • “GS2-02. 12-Year Results of Anastrozole Versus Tamoxifen For the Prevention of Breast Cancer in Postmenopausal Women With Locally Excised Ductal Carcinoma In-Situ” (Sestak et al, SABCS 2020)